Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGENASDAQ:KZRNASDAQ:MACKOTCMKTS:MCUJFNASDAQ:VRNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$3.67$11.07▼$35.71$11.99M1.183,849 shs3,700 shsKZRKezar Life Sciences$0.79-1.4%$0.89$0.67▼$3.13$57.51M0.47692,030 shs574,407 shsMACKMerrimack Pharmaceuticals$14.73+0.1%$14.71$11.53▼$15.89$214.03M1.43110,413 shs82,390 shsMCUJFMedicure$0.80+17.7%$0.82$0.68▼$1.26$8.34M0.921,729 shs3,000 shsVRNAVerona Pharma$15.31+0.5%$16.40$11.83▼$23.81$1.21B0.4494,609 shs499,479 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%0.00%-11.90%+4,340.00%+2,632.31%KZRKezar Life Sciences-2.98%-1.86%-12.42%-2.38%-67.29%MACKMerrimack Pharmaceuticals-0.14%+0.20%-0.14%+10.60%+21.57%MCUJFMedicure+17.54%+0.58%+4.58%-20.11%-16.89%VRNAVerona Pharma-2.25%-7.07%-2.99%-14.77%-32.54%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKZRKezar Life Sciences3.5727 of 5 stars3.21.00.04.61.11.71.3MACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/AN/AN/AN/AVRNAVerona Pharma1.2228 of 5 stars3.52.00.00.00.01.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AKZRKezar Life Sciences2.33Hold$11.001,292.41% UpsideMACKMerrimack PharmaceuticalsN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AVRNAVerona Pharma3.00Buy$33.60119.46% UpsideCurrent Analyst RatingsLatest VRNA, KZR, MACK, MCUJF, and AGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024VRNAVerona PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$31.00 ➝ $36.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/4/2024VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.003/1/2024VRNAVerona PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00KZRKezar Life Sciences$7M8.22N/AN/A$2.58 per share0.31MACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AMCUJFMedicure$16.07M0.52$0.10 per share7.67$1.41 per share0.57VRNAVerona Pharma$460K2,628.99N/AN/A$3.10 per share4.94Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%5/13/2024 (Estimated)KZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)MACKMerrimack Pharmaceuticals-$1.18M-$0.08N/A∞N/AN/A-6.24%-6.09%5/2/2024 (Estimated)MCUJFMedicure-$680K-$0.06N/A∞N/A-4.17%-4.29%-3.14%5/24/2024 (Estimated)VRNAVerona Pharma-$54.37M-$0.69N/AN/AN/AN/A-20.47%-17.72%5/9/2024 (Confirmed)Latest VRNA, KZR, MACK, MCUJF, and AGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024N/AVRNAVerona Pharma-$0.24N/A+$0.24N/AN/AN/A4/8/2024Q4 2023MCUJFMedicureN/A-$0.10-$0.10-$0.10N/A$3.73 million3/14/2024Q4 2023KZRKezar Life Sciences-$0.39-$0.35+$0.04-$0.26N/AN/A3/7/2024Q4 2023MACKMerrimack PharmaceuticalsN/A-$0.01-$0.01-$0.01N/AN/A2/29/2024Q4 2023VRNAVerona Pharma-$0.23-$0.16+$0.07-$0.16N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36KZRKezar Life Sciences0.0511.6611.66MACKMerrimack PharmaceuticalsN/A43.5043.50MCUJFMedicure0.011.921.55VRNAVerona Pharma0.2033.3333.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%KZRKezar Life Sciences67.90%MACKMerrimack Pharmaceuticals63.97%MCUJFMedicureN/AVRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%KZRKezar Life Sciences7.90%MACKMerrimack Pharmaceuticals28.87%MCUJFMedicure12.90%VRNAVerona Pharma4.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableMACKMerrimack Pharmaceuticals42614.53 million10.34 millionOptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableVRNAVerona Pharma7978.99 million76.94 millionOptionableVRNA, KZR, MACK, MCUJF, and AGE HeadlinesSourceHeadlineJennison Associates LLC Acquires 142,819 Shares of Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - April 25 at 7:26 AMVerona Pharma shares target raised on COPD launch outlookinvesting.com - April 25 at 3:40 AMVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Updateglobenewswire.com - April 25 at 2:00 AMVerona Pharma (NASDAQ:VRNA) Price Target Increased to $36.00 by Analysts at Piper Sandleramericanbankingnews.com - April 17 at 3:36 AMVerona Pharma (NASDAQ:VRNA) Trading 3.7% Higher After Analyst Upgradeamericanbankingnews.com - April 17 at 1:08 AMVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.7% on Analyst Upgrademarketbeat.com - April 16 at 10:36 AMVerona Pharma (NASDAQ:VRNA) PT Raised to $36.00 at Piper Sandlermarketbeat.com - April 16 at 8:33 AMVerona Pharma (NASDAQ:VRNA) Shares Up 4.9%marketbeat.com - April 4 at 3:08 PMAmerican Century Companies Inc. Purchases Shares of 280,126 Verona Pharma plc (NASDAQ:VRNA)marketbeat.com - March 28 at 4:07 AMVRNA Apr 2024 17.500 callfinance.yahoo.com - March 16 at 8:32 AMVRNA Apr 2024 15.000 callfinance.yahoo.com - March 16 at 3:31 AMAndrew Fisher Joins Verona Pharma as General Counselglobenewswire.com - March 4 at 2:00 AMBuy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipelinemarkets.businessinsider.com - March 1 at 1:10 PMVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:10 PM3 Healthcare Stocks That Have Outperformed Nvidia Since 2022fool.com - March 1 at 8:45 AMVerona Pharma plc 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 29 at 11:18 AMVerona Pharma plc: Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 10:48 AMVerona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 10:48 AMVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - February 29 at 2:00 AMVerona Pharma earnings preview: what to expectmarkets.businessinsider.com - February 28 at 1:35 PMWhen Will Verona Pharma plc (NASDAQ:VRNA) Turn A Profit?finance.yahoo.com - February 25 at 12:52 PMVerona Pharma PLC ADRwsj.com - February 25 at 7:52 AMVRNA Mar 2024 15.000 putfinance.yahoo.com - February 17 at 7:46 PMVRNA Jun 2024 30.000 callfinance.yahoo.com - February 17 at 2:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Merrimack PharmaceuticalsNASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.MedicureOTCMKTS:MCUJFMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Verona PharmaNASDAQ:VRNAVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.